- Home
- ACLS vs RARE Comparison
ACLS vs RARE Comparison
Compare ACLS & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLS
- RARE
- Stock Information
- Founded
- ACLS 1995
- RARE 2010
- Country
- ACLS United States
- RARE United States
- Employees
- ACLS N/A
- RARE N/A
- Industry
- ACLS Industrial Machinery/Components
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- ACLS Technology
- RARE Health Care
- Exchange
- ACLS Nasdaq
- RARE Nasdaq
- Market Cap
- ACLS 2.2B
- RARE 2.6B
- IPO Year
- ACLS 2000
- RARE 2014
- Fundamental
- Price
- ACLS $78.32
- RARE $27.29
- Analyst Decision
- ACLS Buy
- RARE Strong Buy
- Analyst Count
- ACLS 5
- RARE 14
- Target Price
- ACLS $90.00
- RARE $86.64
- AVG Volume (30 Days)
- ACLS 564.8K
- RARE 2.6M
- Earning Date
- ACLS 08-05-2025
- RARE 08-05-2025
- Dividend Yield
- ACLS N/A
- RARE N/A
- EPS Growth
- ACLS N/A
- RARE N/A
- EPS
- ACLS 4.91
- RARE N/A
- Revenue
- ACLS $896,089,000.00
- RARE $610,159,000.00
- Revenue This Year
- ACLS N/A
- RARE $18.70
- Revenue Next Year
- ACLS $7.41
- RARE $26.76
- P/E Ratio
- ACLS $16.18
- RARE N/A
- Revenue Growth
- ACLS N/A
- RARE 26.77
- 52 Week Low
- ACLS $40.40
- RARE $25.81
- 52 Week High
- ACLS $117.57
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- ACLS 62.21
- RARE 36.56
- Support Level
- ACLS $74.88
- RARE $26.52
- Resistance Level
- ACLS $80.48
- RARE $29.15
- Average True Range (ATR)
- ACLS 3.22
- RARE 1.20
- MACD
- ACLS 0.53
- RARE 0.32
- Stochastic Oscillator
- ACLS 73.06
- RARE 35.29
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.